BioCryst Pharmaceuticals Earnings
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Mon, Nov 2, 2026
Fiscal period
Sep/2026
EPS estimate
$0.10
BioCryst Pharmaceuticals earnings summary
BioCryst Pharmaceuticals is scheduled to report Sep/2026 earnings on Nov 2, 2026, with analysts expecting EPS of $0.10. In its most recent report on Aug 5, 2026 (Q2 2026), BCRX posted EPS of $0.30. Revenue for the quarter was $218.3 million.
Quarterly EPS is up 1400.0% from the same quarter a year earlier. Across the last 16 reports, BCRX shares moved an average of 5.0% (in either direction) in the first trading session after results, rising 10 times and falling 6 times.
Summary generated from market data by MetaCap's automated system. Methodology
BCRX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $0.30 | — | +3.8% |
| May 6, 2026 | — | $-2.98 | — | +4.6% |
| Feb 26, 2026 | — | $1.13 | — | -3.1% |
| Nov 4, 2025 | — | $0.06 | — | -0.1% |
| Aug 5, 2025 | — | $0.02 | — | +0.8% |
| May 6, 2025 | — | $0.00 | — | +2.7% |
| Feb 25, 2025 | — | $-0.13 | — | -10.7% |
| Nov 5, 2024 | — | $-0.07 | — | -9.6% |
| Aug 6, 2024 | — | $-0.06 | — | +0.1% |
| May 7, 2024 | — | $-0.17 | — | +18.0% |
| Feb 27, 2024 | — | $-0.31 | — | -3.4% |
| Nov 8, 2023 | — | $-0.19 | — | +7.4% |
| Aug 7, 2023 | — | $-0.40 | — | +2.2% |
| May 8, 2023 | — | $-0.28 | — | +1.7% |
| Feb 27, 2023 | — | $-0.38 | — | -5.7% |
| Nov 4, 2022 | — | $-0.23 | — | +5.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.